• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit IL-13-dependent proliferation of TF‑1 human erythroleukemic cells. Kitamura, T.     et al. (1989) J. Cell Physiol.     140:323. The ED    ₅₀ for this effect is 0.01‑0.03 µg/mL in the presence of 8 ng/mL of recombinant mouse IL-13.

• Source

  Mouse myeloma cell line, NS0-derived

  Mouse IL-13 R alpha 2 (Leu22 - Lys334) Accession # O88786	IEGRDID	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Leu22

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  63 kDa (monomer)

• SDS-PAGE

  85-90 kDa, reducing conditions

Background: IL-13 R alpha 2

Interleukin-13 Receptor alpha 2 (IL-13 Ra2), also known as IL-13 Ra’, IL-13 binding protein, and CD213a2, is a widely expressed 55 kDa cytokine receptor that plays an important role in the Th2‑polarized immune responses characteristic of a variety of pathologies including parasitic infections and allergic asthma (1, 2). Mature mouse IL-13 Ra2 consists of a 313 amino acid (aa) extracellular domain with three fibronectin type-III domains, a WSxWS motif, a 21 aa transmembrane segment, and a 28 aa cytoplasmic domain (3). Within the ECD, mouse IL-13 Ra2 shares 64% and 94% aa sequence identity with human and rat IL-13 Ra2, respectively. A 40 kDa ‑ 50 kDa soluble form of mouse IL-13 Ra2 can be generated by alternate splicing or MMP-8 mediated shedding (4, 5). The biological effects of IL-13 and IL-4 are closely related in part due to a shared receptor system. IL‑13 binds to IL-13 Ra1 which then forms a signaling complex with IL-4 Ra (6, 7). IL-13 Ra2 functions as a decoy receptor by binding and internalizing IL-13 and preventing it from signaling through the IL-13 Ra1/IL-4 Ra complex (3, 8). IL‑13 Ra2 can also block IL-4 induced responses by inhibiting IL-4 bound IL-13 Ra1/IL-4 Ra receptor complexes even though it does not itself bind IL-4 (9, 10). Aside from its decoy function, IL‑13‑activated IL-13 Ra2 directly promotes the development of tissue fibrosis by inducing the transcription of TGF-beta (11). Soluble IL‑13 Ra2 retains ligand binding capability and attenuates responses to IL-13 but not to IL-4 (9, 12). The up‑regulation of transmembrane and soluble IL‑13 Ra2 during Th2-biased immune responses limits the extent of those responses (13 ‑ 15). IL‑13 Ra2 is expressed in some cancers, and its ability to block IL-13 and IL-4 contributes to tumorigenesis and metastasis (10, 16).

• References:

1. Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.

2. Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.

3. Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.

4. Tabata, Y. et al. (2006) J. Immunol. 177:7905.

5. Chen, W. et al. (2008) J. Allergy Clin. Immunol. 122:625.

6. Andrews, A.-L. et al. (2006) J. Immunol. 176:7456.

7. Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.

8. Caput, D. et al. (1996) J. Biol. Chem. 271:16921.

9. Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.

10. Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.

11. Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.

12. Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.

13. Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.

14. Morimoto, M. et al. (2009) J. Immunol. 183:1934.

15. Zheng, T. et al. (2008) J. Immunol. 180:522.

16. Fujisawa, T. et al. (2009) Cancer Res. 69:8678.

• Long Name:

  Interleukin 13 Receptor alpha 2

• Entrez Gene IDs:

  3598 (Human); 16165 (Mouse)

• Alternate Names:

  cancer/testis antigen 19; CD213a2 antigen; CD213a2; CT19; IL-13 R alpha 2; IL-13 receptor subunit alpha-2; IL13BP; IL13R alpha 2; IL-13R subunit alpha-2; IL13R; IL-13R; IL13RA2; IL-13Ra2; IL-13R-alpha-2; interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; interleukin 13 receptor, alpha 2; interleukin-13 receptor subunit alpha-2; Interleukin-13-binding protein